Tim Smith

This systematic review and meta-analysis looks at trends around the world regarding patients with vitiligo, highlighting prevalence and incidence.

These data are encouraging for tralokinumab, though additional observational research with more individuals with atopic dermatitis or longer follow-up periods may be necessary.

These data reaffirm NB-UVB phototherapy’s use in treating patients with atopic dermatitis and psoriasis, suggesting improvement in patient-reported outcome measures.

This analysis was designed to examine ChatGPT’s accuracy in diagnosing dermatologic conditions among those with and without skin of color.

During this segment of a recent Lungcast, Mora and Sadeameli speak about 2 key topics: vaping and e-cigarette use among children as well as vaccinations and related misinformation.

This analysis was conducted to evaluate the efficacy and safety results of AIT for patients with house dust mite allergies.

In this systematic review and meta-analysis, the investigators highlighted topical roflumilast’s success in clinical milestones such as IGA and PASI score success.

This analysis evaluated the long-term follow-up and risks linked to the self-reported penicillin allergy persistence after a successful oral penicillin challenge and allergy label removal.

These data suggest that the choice of allergens for patch testing should remain the same among individuals with and without atopic dermatitis.

These data on systemic inflammatory biomarkers for patients with eczema may allow for more targeted treatments and for greater personalization of medicine for this skin condition.

The Harris Poll evaluated patient preferences for psoriasis therapy, highlighting patient views through an online survey.

These data highlight the necessity of equality in access to treatment and to the future development of psychological intervention measures using country-specific differences.

This new analysis highlights the effect of this selective allosteric tyrosine kinase 2 inhibitor as an oral treatment for moderate-to-severe psoriasis.

These data on the efficacy of bimekizumab suggest positive therapeutic effects on nail, scalp, and genital lesions as well as quality of life.

In this Lungcast episode, Mora and Sadeameli highlight Asthma Action Plans as well as Asthma Peak Weak considerations for children in the new school year.

Yosipovitch spoke in this interview about the clinical trials leading up to the FDA approval of his nemolizumab for patients with prurigo nodularis.

In this interview, Yosipovitch discusses his team’s findings on nemolizumab and the significance of the drug’s FDA approval for those with prurigo nodularis.

This analysis suggests additional support may be required for tildrakizumab-associated adverse drug reactions, given these new insights.

This study highlights the impact of dietary vitamin E intake on the inflammatory skin condition of atopic dermatitis, also known as eczema.

The results of this analysis can inform clinical decision-making conversations held between patients with eczema and their physicians.

These data highlight the effects on eczema following treatment with dupilumab, tralokinumab, and lebrikizumab in terms of improvements in EASI, IGA, and other measures.

These data suggest that physical activity interventions can lead to visible improvements in PASI scores after 20 weeks of implementation, as well as cardiometabolic improvements.

These data show that izokibep treatment of HS met each of its key primary and key secondary endpoints.

This analysis was conducted to evaluate the effect of pruritus on quality of life ratings among individuals with atopic dermatitis and psoriasis.

In this analysis, the biggest predictors of biologic initiation among individuals with diagnoses of psoriasis were evaluated.

The drug is the first approved monoclonal antibody specifically designed to inhibit the IL-31 pathway, a driver of prurigo nodularis.

This analysis highlights data regarding agreement between various smartphone applications used for detection of melanoma.

In this interview, Kim speaks about the significance of the FDA approval of neffy for patients who face the threat of anaphylaxis and other severe allergic reactions.

This analysis compared drug survival rates of abrocitinib and dupilumab in the treatment of adults with eczema, with different benefits highlighted for both therapies.

In this analysis, investigators compared deucravacitinib in terms of patient-reported outcomes versus those of placebo and apremilast.